Study Review: Polatuzumab Vedotin in Treatment-Naive Diffuse Large B-Cell Lymphoma
This review summarises key aspects and clinical practice implications of POLARIX, a phase 3 randomised controlled trial that evaluated Pola-R-CHP, a modified regimen of R-CHOP (rituximab added to cyclophosphamide, doxorubicin, vincristine, and prednisone) in which vincristine was replaced with polatuzumab vedotin, compared with standard R-CHOP in patients with previously-untreated diffuse large B-cell lymphoma (DLBCL). The main findings were a statistically significant progression-free survival benefit at two years in patients who received Pola-R-CHP versus those who received R-CHOP and a similar safety profile in the two treatment groups. These findings have been confirmed in a 5-year follow-up analysis of POLARIX. This publication has been commissioned and funded by Roche.
Expert contributor
Dr Leanne Berkahn
Leanne Berkahn is a consultant haematologist at Auckland City Hospital and senior lecturer in the Department of Molecular Medicine and Pathology at the University of Auckland School of Medicine. Her current research interests are new therapeutic approaches in the management of leukaemia and lymphoma.
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.
